 |
Gilmartin Group and Canale Communications represent Imago BioSciences, which has agreed to be acquired by Merck for $1.4B.
The South San Francisco-based company is a clinical-stage biopharma that develops treatments for bone marrow diseases.
“This agreement leverages Merck’s industry-leading clinical development expertise to maximize the therapeutic potential of bomedemstat, which is currently in Phase 2 trials while providing important value for shareholders,” said Dr. Hugh Rienhoff, founder/CEO of Imago.
“This acquisition of Imago augments our pipeline and strengthens our presence in the growing field of hematology,” added Robert Davis, Merck CEO.
Gilmartin Group’s Laurence Wells handles the investment community for Imago, while Canale Communications' Ian Stone works the media.
Edelman handles Viking Holdings, the river and ocean luxury cruise line that plans to raise $1B via an IPO priced in the $21 to $25 per share range.
Teneo is handling the initial public offering of CVC Capital Partners, one of Europe’s largest private equity firms with nearly $200B in assets under management.
Brunswick Group represents Endeavor Group Holdings as it agrees to go private via its acquisition by Silver Lake technology investment firm, which is handled by Edelman Smithfield.
Tod Donhauser, a nine-year veteran of Edelman, has joined H/Advisors Abernathy as managing director and head of its San Francisco office.
Have a comment? Send it to 
No comments have been submitted for this story yet.